


Biolligence
Biotechnology Research • Oxford, England, United Kingdom • 1-10 Employees
Company overview
| Headquarters | Oxford, England, United Kingdom |
| Website | |
| NAICS | 541714 |
| Employees | 1-10 |
Key Contact at Biolligence
Satyan Chintawar
COO and Co-Founder of Bioligence
Biolligence Email Formats
Biolligence uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@biolligence.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@biolligence.com | 100% |
About Biolligence
Biolligence is revolutionizing the field of drug discovery by addressing one of the industry’s biggest challenges: accurately predicting human-specific drug toxicity and efficacy. Traditional drug development heavily relies on animal models, which often fail to accurately translate to human outcomes. This results in high failure rates in clinical trials, costly delays, and prolonged time to market for life-saving treatments. We help companies in their precision medicine design goals. Here's why Biolligence stands out: Human-Centric Data: Our platform generates human-relevant, population-based data, enabling more precise predictions of drug responses across diverse genetic and demographic backgrounds. This approach increases the accuracy of toxicity predictions, supporting more effective and safer clinical trial designs. Advanced AI-Driven Insights: Leveraging cutting-edge AI algorithms, Biolligence provides deep, explainable insights into drug toxicity mechanisms. This allows researchers to uncover hidden safety liabilities early in the process, reducing the likelihood of late-stage failures and costly setbacks. Ethical and Efficient: By reducing reliance on animal testing, we not only address ethical concerns but also offer a more efficient, scalable alternative. Our approach aligns with the global shift toward humane and sustainable research practices in drug discovery. Precision and Speed: Our platform accelerates the path to precision-designed clinical trials, providing faster and more accurate predictions that help biopharma companies make better-informed decisions sooner. This ultimately reduces the cost and time associated with bringing safer, more effective drugs to market. Choose Biolligence to elevate your drug discovery process with precision, reliability, and human
Biolligence revenue & valuation
| Annual revenue | $256,665 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $821,328 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Biolligence has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Biolligence has never raised funding before.
Frequently asked questions
4.8
40,000 users



